Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency

Journal of Lipid Research

Volumn 37, Issue 3, 1996, Pages 640-650

  Bijvoet, S ^a,b   Gagne S E ^a   Moorjani, S ^c   Gagne C ^c   Henderson, H E ^a,f   Fruchart, J C ^d   Dallongeville, J ^d   Alaupovic, P ^e   Prins, M ^e   Kastelein, J J P ^b   Hayden, M R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITÉ LAVAL   (Canada)

^d INSTITUT PASTEUR DE LILLE   (France)

^e OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

heterozygotes; lipoprotein lipase; lipoproteins; LPL deficiency

Indexed keywords

APOLIPOPROTEIN; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MONOACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AMINO ACID SUBSTITUTION; CATALYSIS; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; LIPID COMPOSITION; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REVIEW;

ADULT; AGING; APOLIPOPROTEINS; CHILD; CHOLESTEROL; COHORT STUDIES; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; LIPOPROTEIN LIPASE; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; MUTATION; PEDIGREE; PHENOTYPE; QUEBEC; TRIGLYCERIDES;

EID: 15844426908     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Brunzell, J. D. 1995. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In The Metabolic and Molecular Basis of Inherited Disease. C. Scriver, A. I. Beaudet, W. S. Sly and D. Valle, editors. McGraw-Hill Book Co., New York. Vol. II. 1913-1933.
2. Beisiegel, U., W. Weber, and G. Bengtsson-Olivecrona. 1991. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. USA. 88: 342-8346.
3. Aviram, M., E. L. Bierman, and A. Chait. 1988. Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces cell enhanced uptake and cholesterol accumulation in cells. J. Biol. Chem. 263: 15416-15422.
4. Mulder, M., P. Lombardi, H. Jansen, T. J. C. van Berkel, R. R. Frants, and L. M. Havekes. 1993. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J. Biol. Chem. 268: 9369-9375.
5. Rumsey, S. C., J. C. Obunike, Y. Arad, R. J. Deckelbaum, and I. J. Goldberg. 1992. Lipoprotein lipase-mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages. J. Clin. Invest. 90: 1504-1512.
6. Williams, K. J., K. A. Petrie, R. W. Brocia, and T. L. Swenson. 1991. Lipoprotein lipase modulates net secretary output of apolipoprotein B in vitro: a possible pathophysiologic explanation for familial hyperlipidemia. J. Clin. Invest. 88: 1300-1306.
7. Langlois, S., S. Deeb, J. D. Brunzell, J. D. J. J. Kastelein, and M. R. Hayden. 1989. A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. Proc. Natl. Acad. Sci. USA. 86: 948-952.
8. Ameis, D., J. Kobayashi, R. C. Davis, O. Ben-Zeev, M. J. Malloy, J. P. Kane, G. Lee, H. Wong, R. J. Havel, and M. C. Schotz. 1991. Familial hyperchylomicronemia due to a single missense mutation in the lipoprotein lipase gene. J. Clin. Invest. 87: 1165-1170.
9. Emi, M., D. E. Wilson, P-H. Iverius, L. L. Wu, A. Hata, R. Hegele, R. R. Williams, and J-M. Lalouel. 1990. Missense mutation (Gly-Gly188) of human lipoprotein lipase imparting functional deficiency. J. Biol. Chem. 265: 5910-5916.
10. Ma, Y., M-S. Liu, D. Ginzinger, J. Frolich, J. D. Brunzell, and M. R. Hayden. 1993. Gene environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172 → Cys mutation in the lipoprotein lipase gene. J. Clin. Invert. 91: 1953-1958.
11. Zhang, H., P. Reymer, M. S. Liu, I. J. Forsythe, B. E. Groenemeyer, J. Frolich, J. D. Brunzell, J. P. Kastelein, M. R. Hayden, and Y. Ma. 1995. Patients with apoE3 deficiency (E2/2, E3/2 and E4/4) who manifest with hyperlipidemia have increased frequency of an Asn291Ser mutation in the LPL gene. Arterioscler. Thromb. Vasc. Biol. 15: 1695-1703.
12. Reymer, P. W. A., B. E. Groenemeyer, E. Gagne, Li. Miao, E. E. G. Appleman, J. C. Seidel, D. Kromhout, S. M. Bijvoet, K. van der Oever, T. Bruin, M. R. Hayden, and J. J. P. Kastelein. 1995. A frequently occurring mutation in the lipoprotein lipase gene (Asp291Ser) contributes to the expression of Familial Combined Hyperlipidemia. Hum. Mol. Genet. 4: 1543-1549.
13. Reymer, P. W. A., E. Gagne, B. E. Groenemeyer, H. Zhang, I. Forsythe, H. Jansen, J. C. Seidell, D. Kromhout, K. E. Lie, J. J. P. Kastelein, and M. R. Hayden. 1995. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat. Genet. 10: 28-34.
14. Wilson, D. E., M. Emi, P-H. Iverius, A. Hata, L. L. Wu, E. Hillas, R. R. Williams, and J-M. Lalouel. 1990. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. J. Clin. Invest. 86: 735-750.
15. Miesenbock, G., B. Holz, B. Foger, E. Brandstatter, B. Paulweber, F. Sandhofer, and J. R. Patsch. 1993. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J. Clin. Invest. 91: 448-455.
16. Ma, Y., H. E. Henderson, M. R. Ven Murthy, G. Roederer, M. V. Monsalve, L. A. Clarke, T. Normand, P. Julien, G. Gagné, M. Lambert, and M. R. Hayden. 1991. A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians. N. Engl. J. Med. 324: 761-766.
17. Normand, T., J. Bergeron, T. Fernandez-Margallo, A. Bharucha, M. R. Ven Murthy, P. Julien, C. Gagné, C. Dionne, M. De Braekeleer, M. R. Hayden, and P. Lupien. 1992. Geographic distribution and genealogy of mutation 207 of lipoprotein lipase gene in the French Canadian population of Quebec. Hum. Genet. 89: 671-675.
18. Monsalve, M. V., H. E. Henderson, G. Roederer, P. Julien, S. S. Deeb, J. J. P. Kastelein, L. N. Peritz, R. H. Devlin, T. Bruin, M. R. Ven Murthy, C. Gagne, J. Davignon, P. J. Lupien, J. D. Brunzell, and M. R. Hayden. 1990. A missense mutation at codon 188 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in persons of different ancestries. J. Clin. Invest. 86: 728-734.
19. Ma, Y., B. I. Wilson, S. Bijvoet, H. E. Henderson, E. Cramb, G. Roederer, M. R. Ven Murthy, P. Julien, H. D. Bakker, J. J. P. Kastelein, J. D. Brunzell, and M. R. Hayden. 1992. A missense mutation (Asp250 → Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. Genomics. 13: 649-653.
20. Pimstone, S. N., E. Gagne, C. Gagne, P. J. Lupien, D. Gaudet, R. R. Williams, M. Kotze, P. W. A. Reymer, J. C. Defesche, J. J. P. Kastelein, S. Moorjani, and M. R. Hayden. 1995. Mutations in the gene for lipoprotein lipase: a cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15: 1704-1712.
21. Havel, R. J., H. Eder, and H. F. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
22. Curry, M. P., P. Alaupovic, and C. A. Suenram. 1976. Determination of apolipoprotein A and its constitutive AI and AII polypeptides by separate electroimmunoassays. Clin. Chem. 22: 315-322.
23. Curry, M. D., P. Alaupovic, and C. A. Suenram. 1978. Electroimmunoassay, radioimmunoassay and radial immunodiffusion assay evaluated for quantification of human apolipoprotein B. Clin. Chem. 24: 280-286.
24. Gidez, L. I., G. J. Miller, M. Burstein, S. Slagle, and H. A. Eder. 1982. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J. Lipid Res. 23: 1206-1223.
25. Curry, M. D., W. J. McConathy, J. D. Fesmire, and P. Alaupovic. 1978. Quantitative determination of human lipoprotein CIII by electroimmunoassay. Biochim. Biophys. Acta. 617: 503-513.
26. Leroy, A., N. VuDAC, M. Koffigan, V. Clavey, and J. C. Fruchart. 1988. Characterization of monoclonal antibody that binds to apoE and to lipoprotein of human plasma containing apoE. Applications to ELISA quantification of plasma apoE. J. Immunol. 9: 309-334.
27. Parra, H. J., H. Mezdour, N. Ghalim, J. M. Bard, and J. C. Fruchart. 1990. Differential electroimmunoassay of human LpAI lipoprotein particles on ready-to-use plates. Clin. Chem. 36: 1431-1435.
28. Searle, S. R. 1971. Linear Models. Wiley & Sons Inc., New York.
29. Sammett, D., and A. R. Tall. 1985. Mechanisms of enhancement of cholesterol ester transfer protein activity by lipolysis. J. Biol. Chem. 260: 6687-6697.
30. Tall, A., E. Granot, R. Brocia, I. Tabas, C. Hesler, K. Williams, and M. Denke. 1987. Accelerated transfer of cholesterol esters in dyslipidemic plasma: role of cholesterol ester transfer protein. J. Clin. Invest. 79: 1217-1225.
31. Eisenberg, S., and T. Olivecrona. 1979. Very low density lipoprotein. Fate of phospholipids, cholesterol, and apolipoprotein C during lipolysis in vitro. J. Lipid Res. 20: 614-623.
32. Kleinman, Y., S. Eisenberg, Y. Oschry, D. Gavish, O. Stein, and Y. Stein. 1985. Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. J. Clin. Invest. 75: 1796.
33. Eisenberg, S. 1987. Lipoprotein abnormalities in hypertriglyceridemia: significance in atherosclerosis. Am. Heart J. 113: 555-561.
34. Babirak, S. P., P-H. Iverius, W. F. Fujimoto, and J. D. Brunzell. 1989. Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis. 9: 326-334.
35. Yang, W. S., D. N. Nevin, R. Peng, J. D. Brunzell, and S. S. Deeb. 1995. A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with Familial Combined Hyperlipidemia and low LPL activity. Proc. Natl. Acad. Sci. USA. 92: 4462-4466.
36. Alaupovic, P. 1981. The David Rubinstein Memorial Lecture: The biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can. J. Biochem. 59: 565-579.
37. Eisenberg, S. 1985. A dynamic evaluation of the plasma fat transport system. Klin. Wochenschr. 61: 119-132.
38. Tam, S. P., L. Dory, and D. Rubinstein. 1981. Fate of apolipoproteins C-II, C-III and E during lipolysis of human very low density lipoproteins in vitro. J. Lipid Res. 22: 641-651.
39. Blankenhorn, D. H., P. Alaupovic, E. Wickham, H. P. Chin, and S. P. Azen. 1990. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Circulation. 81: 470-476.
40. Hodis, H. N., W. J. Mack, S. P. Azen, P. Alaupovic, J. M. Pogoda, L. LaBree, L. C. Hemphill, D. M. Kramsch, and D. H. Blankenhorn. 1994. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90: 42-49.
41. Le, N. A., J. C. Gibson, and H. N. Ginsberg. 1988. Independent regulation of plasma lipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: Implication for the regulation of the catabolism of these lipoproteins. Lipid Res. 29: 669-677.
42. Carlson, L. A., and D. Ballantyne. 1976. Changing relative proportions of apolipoproteins C-II and C-III of very low density lipoproteins in hypertriglyceridemia. Atherosclerosis. 23: 563-568.
43. Leitersdorf, E., N. Gottehrer, M. Fainaru, Y. Friedlander, G. Friedman, D. Tzivoni, and Y. Stein. 1986. Analysis of risk factors in 532 survivors of first myocardial infarction hospitalized in Jerusalem. Atherosclerosis. 59: 75-93.
44. Schwartzkopf, W., J. Schleicher, I. Pottins, S. Yu, C. Han, and D. Du. 1990. Lipids, lipoproteins, apolipoproteins and other risk factors in Chinese men and women with and without myocardial infarction. Atherosclerosis. 82: 253-259.
45. Mowri, H-O., J. R. Patsch, A. Ritsch, B. Föger, S. Brown, and W. Patsch. 1994. High density lipoproteins with differing apolipoproteins: relationship to postprandial lipemia, cholesteryl ester transfer protein, and activities of lipoprotein lipase, hepatic lipase, and lecithin:cholesterol acyltransferase. J. Lipid Res. 35: 291-300.
46. Barbaras, R., P. Puchois, J-C. Fruchart, and G. Ailhaud. 1987. Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAII:AI particles. Biochem. Biophys. Res. Commun. 142: 63-69.
47. Puchois, P., A. Kandoussi, P. Fievet, J. L. Fourrier, M. Bertrand, E. Koren, and J-C. Fruchart. 1987. Apolipoprotein A-I-containing lipoproteins in coronary artery disease. Atherosclerosis. 68: 35-40.
48. Parra, H. J., D. Arveiler, A. E. Evans, J. P. Cambou, P. Amouyel, A. Bingha, D. McMaster, P. Schaffer, P. Douste-Blaxy, G. Luc, J. L. Richard, P. Ducimetiere, J. C. Fruchart, and F. Cambien. 1991. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler. Thromb. 12: 701-707.
49. Coleman, T., R. L. Seip, J. M. Gimbel, D. Lee, N. Maeda, and C. F. Semenkovich. 1995. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J. Biol. Chem. 270: 12518-12525.
50. Ginzinger, D. G., M. E. S. Lewis, Y. Ma, B. R. Jones, G. Liu, S. D. Jones, and M. R. Hayden. 1996. A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats. J. Clin. Invest. 97: 1257-1266.